Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs GR MD 02 (Primary)
- Indications Fibrosis; Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Acronyms NASH-FX
- Sponsors Galectin Therapeutics
- 22 Feb 2017 Status changed from active, no longer recruiting to completed.
- 15 Nov 2016 Baseline patient characteristics and non-invasive assessment data, presented at The Liver Meeting 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases.
- 07 Oct 2016 According to a Galectin Therapeutics media release, data evaluating utility of non-invasive imaging methods in NASH-FX and NASH-CX trial to be presented at The Liver Meeting 2016 .